Table 1 Association between the CILP2 mRNA expression and clinicopathological characteristics of the patients included in the validation cohort.
Variables | High CILP2 (n = 42) | Low CILP2 (n = 74) | P value* |
|---|---|---|---|
Age (years), mean ± SD | 59.50 ± 10.49 | 59.26 ± 11.93 | 0.91 |
Sex | 0.44 | ||
 Male | 23 (55%) | 46 (62%) |  |
 Female | 19 (45%) | 28 (38%) |  |
Preoperative CEA, ng/mL | 0.15 | ||
 ≤ 5 | 24 (57%) | 53 (72%) |  |
 > 5 | 18 (43%) | 21 (28%) |  |
Peritoneal metastases | 0.00008 | ||
 Negative | 21 (50%) | 63 (85%) |  |
 Positive | 21 (50%) | 11 (15%) |  |
Liver metastases | 0.51 | ||
 Negative | 30 (71%) | 57 (77%) |  |
 Positive | 12 (29%) | 17 (23%) |  |
Lung metastases | 0.17 | ||
 Negative | 33 (79%) | 66 (89%) |  |
 Positive | 9 (21%) | 8 (11%) |  |
Differentiation | 0.02 | ||
 Differentiated | 32 (76%) | 69 (93%) |  |
 Undifferentiated | 10 (24%) | 5 (7%) |  |
AJCC stage | 0.02 | ||
 I | 0 (0%) | 1 (1%) |  |
 II | 9 (21%) | 31 (42%) |  |
 III | 11 (26%) | 23 (31%) |  |
 IV | 22 (52%) | 19 (26%) |  |
